No Data
No Data
No Data
No Data
No Data
Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating EIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
SOUTH SAN FRANCISCO, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cr
GlobeNewswireMay 1 20:00
Denali Therapeutics(DNLI.US) Director Sells US$30,471.14 in Common Stock
$Denali Therapeutics(DNLI.US)$ Director SATO VICKI L sold 1,666 shares of common stock on Apr 15, 2024 at an average price of $18.29 for a total value of $30,471.14.Source: Announcement What is statem
Futu NewsApr 18 05:54
Denali Therapeutics Inc.'s (NASDAQ:DNLI) Low P/S No Reason For Excitement
Denali Therapeutics Inc.'s (NASDAQ:DNLI) price-to-sales (or "P/S") ratio of 7.9x might make it look like a buy right now compared to the Biotechs industry in the United States, where around half of th
Simply Wall StApr 15 18:48
GLP-1s Benefit Parkinson's: Barclays Sees Implications Across Biopharma
Seeking AlphaApr 13 00:02
Denali Therapeutics Is Maintained at Buy by UBS
Denali Therapeutics Is Maintained at Buy by UBS
Dow JonesApr 10 00:15
UBS: Maintains Denali Therapeutics (DNLI.US) rating, adjusted from buy to buy rating, and adjusted target price from $70.00 to $32.00.
UBS: Maintains Denali Therapeutics (DNLI.US) rating, adjusted from buy to buy rating, and adjusted target price from $70.00 to $32.00.
Zhitong FinanceApr 10 00:10
No Data
No Data